Literature DB >> 26202870

Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene.

Aung Ko Win1, Jeanette C Reece2, Daniel D Buchanan2,3, Mark Clendenning3, Joanne P Young4,5,6, Sean P Cleary7, Hyeja Kim7, Michelle Cotterchio8, James G Dowty2, Robert J MacInnis2,9, Katherine M Tucker10, Ingrid M Winship11,12, Finlay A Macrae12,13, Terrilea Burnett14, Loïc Le Marchand14, Graham Casey15, Robert W Haile16, Polly A Newcomb17,18, Stephen N Thibodeau19, Noralane M Lindor20, John L Hopper2,21, Steven Gallinger7, Mark A Jenkins2.   

Abstract

The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G>A p.(Gly396Asp), 3 with c.821G>A p.(Arg274Gln), and 1 with c.536A>G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio (HR) 21.5, 95% confidence interval (CI) 9.19-50.1; p < 0.001], but not different from that for carriers of a MMR gene mutation alone (HR 1.94, 95% CI 0.63-5.99; p = 0.25). Within the limited power of this study, there was no evidence that a monoallelic MUTYH gene mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation alone. Our finding suggests MUTYH mutation testing in MMR gene mutation carriers is not clinically informative.

Entities:  

Keywords:  Colorectal cancer; Lynch syndrome; MUTYH; Mismatch repair

Mesh:

Substances:

Year:  2015        PMID: 26202870      PMCID: PMC4631636          DOI: 10.1007/s10689-015-9824-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  34 in total

1.  A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer.

Authors:  P Maillet; P O Chappuis; G Vaudan; Z Dobbie; H Müller; P Hutter; A P Sappino
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

2.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.

Authors:  Melissa C Southey; Mark A Jenkins; Leeanne Mead; Jonathan Whitty; Melanie Trivett; Andrea A Tesoriero; Letitia D Smith; Kim Jennings; Garry Grubb; Simon G Royce; Michael D Walsh; Melissa A Barker; Joanne P Young; Jeremy R Jass; D James B St John; Finlay A Macrae; Graham G Giles; John L Hopper
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

3.  A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes.

Authors:  Antonis C Antoniou; David E Goldgar; Nadine Andrieu; Jenny Chang-Claude; Richard Brohet; Matti A Rookus; Douglas F Easton
Journal:  Genet Epidemiol       Date:  2005-07       Impact factor: 2.135

4.  Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.

Authors:  Kandelaria Rumilla; Karen V Schowalter; Noralane M Lindor; Brittany C Thomas; Kara A Mensink; Steven Gallinger; Spring Holter; Polly A Newcomb; John D Potter; Mark A Jenkins; John L Hopper; Tiffany I Long; Daniel J Weisenberger; Robert W Haile; Graham Casey; Peter W Laird; Loic Le Marchand; Stephen N Thibodeau
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

5.  Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MYH.

Authors:  Heike Görgens; Stefan Krüger; Eberhard Kuhlisch; Constanze Pagenstecher; Ruth Höhl; Hans K Schackert; Annegret Müller
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

6.  Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer.

Authors:  S Kong; C I Amos; R Luthra; P M Lynch; B Levin; M L Frazier
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation.

Authors:  Rebecca Felix; Walter Bodmer; Nicola S Fearnhead; Lize van der Merwe; Paul Goldberg; Rajkumar S Ramesar
Journal:  Mutat Res       Date:  2006-12-01       Impact factor: 2.433

8.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

9.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

10.  Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study.

Authors:  Sean P Cleary; Michelle Cotterchio; Mark A Jenkins; Hyeja Kim; Robert Bristow; Roger Green; Robert Haile; John L Hopper; Loic LeMarchand; Noralane Lindor; Patrick Parfrey; John Potter; Ban Younghusband; Steven Gallinger
Journal:  Gastroenterology       Date:  2008-12-27       Impact factor: 22.682

View more
  5 in total

1.  Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer.

Authors:  Afaf Elsaid; Rami Elshazli; Fatma El-Tarapely; Hossam Darwish; Camelia Abdel-Malak
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

Review 2.  When you're strange: Unusual features of the MUTYH glycosylase and implications in cancer.

Authors:  Alan G Raetz; Sheila S David
Journal:  DNA Repair (Amst)       Date:  2019-06-08

3.  An Individual with Both MUTYH-Associated Polyposis and Lynch Syndrome Identified by Multi-Gene Hereditary Cancer Panel Testing: A Case Report.

Authors:  Stephanie A Cohen; Christopher A Tan; Ryan Bisson
Journal:  Front Genet       Date:  2016-03-16       Impact factor: 4.599

4.  Digenic inheritance of MSH6 and MUTYH variants in familial colorectal cancer.

Authors:  Stephanie A Schubert; Dina Ruano; Yvonne Tiersma; Mark Drost; Niels de Wind; Maartje Nielsen; Liselotte P van Hest; Hans Morreau; Noel F C C de Miranda; Tom van Wezel
Journal:  Genes Chromosomes Cancer       Date:  2020-07-02       Impact factor: 5.006

5.  Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.

Authors:  Aung Ko Win; Jeanette C Reece; James G Dowty; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Melissa C Southey; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; Finlay A Macrae; Katherine M Tucker; John A Baron; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; John L Hopper; Steven Gallinger; Ingrid M Winship; Noralane M Lindor; Mark A Jenkins
Journal:  Int J Cancer       Date:  2016-06-02       Impact factor: 7.316

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.